Literature DB >> 23010745

Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease.

John A Hermos1, Arman Altincatal, H Christian Weber, Kelly Grotzinger, Kyle J Smoot, Kelly Cho, David R Gagnon, Elizabeth V Lawler.   

Abstract

BACKGROUND: Thrombocytopenia in chronic liver disease (CLD) typically reflects disease severity and may indicate an increased risk for bleeding. AIMS: To describe the longitudinal course of thrombocytopenia and risks for bleeding in veteran patients with non-hepatitis C-related CLD.
METHODS: We identified 2,349 patients with non-hepatitis C-related CLD from databases of the New England Veterans Healthcare System between 1999 and 2008. The cohort was stratified by baseline platelet counts of <50,000, 50-100,000, > 100,000-150,000, and >150,000/μl. Primary outcomes were the incidence and hazard rates for bleeding episodes requiring hospitalization and incident severe thrombocytopenia (<50,000/μl).
RESULTS: Over a median follow-up of 3.3 years (IQR 1.2, 6.3), incident major bleeds, predominantly gastrointestinal, occurred in 254 patients (10.8 % of the cohort) and in 19.9 % of those with baseline platelets <50,000/μl. Incident severe thrombocytopenia occurred in 315 patients (13.4 % of cohort) and in 40.7 % of those with baseline platelet counts between 50,000 and 100,000/μl. Baseline platelet counts between 50,000 and 100,000/μl independently predicted bleeding [adjusted HR 2.89 (1.76, 4.73) p < 0.001] as did esophageal varices, hemoglobin ≤ 9.9 g %, and INR 1.4-2.0. Incident severe thrombocytopenia and minimum platelet counts <25,000/μl each associated with bleeding episodes, but the average of minimum platelet counts recorded for those who bled was 76,000/μl.
CONCLUSIONS: Among veteran patients with non-hepatitis C-related CLD, baseline platelet counts of 50,000 to 100,000/μl increased subsequent risks for both incident severe thrombocytopenia and major bleeding events. Whereas associations between severe thrombocytopenia and bleeding most likely reflect CLD severity, liver-related coagulopathies, and co-morbid bleeding risks, interventions to enhance platelet production may be beneficial for such patients.

Entities:  

Mesh:

Year:  2012        PMID: 23010745     DOI: 10.1007/s10620-012-2404-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

Review 1.  Review article: coagulation disorders in chronic liver disease.

Authors:  M Peck-Radosavljevic
Journal:  Aliment Pharmacol Ther       Date:  2007-11       Impact factor: 8.171

Review 2.  The coagulopathy of chronic liver disease.

Authors:  Armando Tripodi; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

Review 3.  A review of the treatment of chronic hepatitis C virus infection in cirrhosis.

Authors:  Elena Vezali; Alessio Aghemo; Massimo Colombo
Journal:  Clin Ther       Date:  2010-12       Impact factor: 3.393

4.  Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Authors:  Robert Roomer; Bettina E Hansen; Harry L A Janssen; Robert J de Knegt
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

5.  Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark.

Authors:  Henrik Toft Sørensen; Ane Marie Thulstrup; Lene Mellemkjar; Peter Jepsen; Erik Christensen; Jørgen H Olsen; Hendrik Vilstrup
Journal:  J Clin Epidemiol       Date:  2003-01       Impact factor: 6.437

Review 6.  Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options.

Authors:  E G Giannini
Journal:  Aliment Pharmacol Ther       Date:  2006-04-15       Impact factor: 8.171

7.  Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis.

Authors:  E Giannini; F Botta; P Borro; D Risso; P Romagnoli; A Fasoli; M R Mele; E Testa; C Mansi; V Savarino; R Testa
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 8.  Review article: thrombocytopenia in chronic liver disease.

Authors:  F Poordad
Journal:  Aliment Pharmacol Ther       Date:  2007-11       Impact factor: 8.171

Review 9.  Thrombocytopenia associated with chronic liver disease.

Authors:  Nezam Afdhal; John McHutchison; Robert Brown; Ira Jacobson; Michael Manns; Fred Poordad; Babette Weksler; Rafael Esteban
Journal:  J Hepatol       Date:  2008-03-31       Impact factor: 25.083

10.  Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.

Authors:  Kung-Hung Lin; Ping-I Hsu; Hsien-Chung Yu; Chun-Ku Lin; Wei-Lun Tsai; Wen-Chi Chen; Hoi-Hung Chan; Kwok-Hung Lai
Journal:  BMC Gastroenterol       Date:  2012-01-18       Impact factor: 3.067

View more
  2 in total

1.  Thrombocytopenia in patients with chronic liver disease: what's in a name?

Authors:  Edoardo G Giannini
Journal:  Dig Dis Sci       Date:  2013-02       Impact factor: 3.199

2.  Splenic artery embolization with detachable balloons for hypersplenism.

Authors:  Xiaoxi Pang; Tengyu Li; Cheng'en Wang
Journal:  J Int Med Res       Date:  2018-07-20       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.